BNGO · Bionano Genomics, Inc. · Webcasts, Transcripts & Audio
$1.00
-0.04 (-3.85%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Nov 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, we determined that there is substantial doubt about our ability to continue as a going concern within 12 months after the date that the financial statements included in this Quarterly Report are issued.”View the 10-Q filed Nov 10, 2026
Market Cap
$13.99M
Shares
13.99M
Volume · Nov 13
557.57K
Avg daily vol (3M)
965.62K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Bionano Genomics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Bionano Genomics, Inc. (BNGO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-10
Bionano Genomics, Inc. (BNGO) Q3 2026 Earnings Call
Revenue
$8.28M
▲ 12.3% YoY Diluted EPS
$-0.54
Gross margin
47.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-10
Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call Transcript
Confident tone
Clinical adoption and consumables growth
OGM utilization and installed base
Software and VIA expansion
Revenue
$8.17M
▲ 21.4% YoY Diluted EPS
$-0.64
Gross margin
52.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
Positive tone
OGM Installed Base & Utilization
Reimbursement & CPT Codes
Publications & Clinical Evidence
Revenue
$6.69M
▲ 3.6% YoY Diluted EPS
$-0.76
Gross margin
48.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-23
Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript
Positive tone
OGM scaling and key customer adoption
Gross margin and cost transformation
Reimbursement and guideline inclusion
Revenue
$7.95M*
▼ 2.6% YoY Gross margin
42.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Bionano Genomics, Inc. (BNGO) Q3 2025 Earnings Call Transcript
Positive tone
Routine user utilization strategy
Publications and clinical evidence
Revenue and product mix
Revenue
$7.37M
▲ 21.3% YoY Diluted EPS
$-1.59
Gross margin
45.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Bionano Genomics, Inc. (BNGO) Q2 2025 Earnings Call Transcript
Positive tone
VIA software and digital pathology expansion
Strategic shift to routine user focus
Flow cell consumables growth
Revenue
$6.73M
▼ 13.4% YoY Diluted EPS
$-1.99
Gross margin
51.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Bionano Genomics, Inc. (BNGO) Q1 2025 Earnings Call Transcript
Balanced tone
Strategic shift to routine/high-utilization users
Cost reduction and profitability
Publications and clinical evidence
Revenue
$6.46M
▼ 26.4% YoY Diluted EPS
$-1.15
Gross margin
45.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q3
2024-11-13
Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript
Cautious tone
Consumables utilization and flow cell growth
Stratys system commercialization
Revenue decline and guidance reduction
Revenue
$6.07M
▼ 34.8% YoY Diluted EPS
$-30.92
Gross margin
-139.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Bionano Genomics, Inc. (BNGO) Q2 2024 Earnings Call Transcript
Cautious tone
Stratys system adoption
Software and partnerships (VIA, Revvity)
Reimbursement and CPT code milestone
Revenue
$7.77M
▼ 10.3% YoY Diluted EPS
$-14.41
Gross margin
33.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Bionano Genomics, Inc. (BNGO) Q1 2024 Earnings Call Transcript
Positive tone
Biopharma and OGM adoption
Ionic purification system
Cost reduction and cash runway
Revenue
$8.77M
▲ 18.3% YoY Diluted EPS
$-35.75
Gross margin
32.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Bionano Genomics, Inc. (BNGO) Q4 2023 Earnings Call Transcript
Balanced tone
Revenue growth and installed base expansion
Stratys system adoption
Cost reduction and restructuring
Revenue
$10.72M*
▲ 30.5% YoY Gross margin
22.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-11
Bionano Genomics, Inc. (BNGO) Q3 2023 Earnings Call Transcript
Revenue
$9.32M
▲ 29% YoY Diluted EPS
$-193.20
Gross margin
29.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Bionano Genomics, Inc. (BNGO) Q2 2023 Earnings Call Transcript
Revenue
$8.66M
▲ 29.9% YoY Diluted EPS
$-74.40
Gross margin
26.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-24
Bionano Genomics, Inc. (BNGO) Q1 2023 Earnings Call Transcript
Revenue
$7.42M
▲ 30.2% YoY Diluted EPS
$-73.80
Gross margin
27.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-05
Bionano Genomics, Inc. (BNGO) Q4 2022 Earnings Call Transcript
Revenue
$8.21M*
▲ 30.4% YoY Gross margin
22.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Bionano Genomics, Inc. (BNGO) Q3 2022 Earnings Call Transcript
Revenue
$7.22M
▲ 55.1% YoY Diluted EPS
$-66.00
Gross margin
25.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Bionano Genomics, Inc. (BNGO) Q2 2022 Earnings Call Transcript
Revenue
$6.67M
▲ 73% YoY Diluted EPS
$-67.80
Gross margin
22.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Bionano Genomics, Inc. (BNGO) Q1 2022 Earnings Call Transcript
Revenue
$5.70M
▲ 79.8% YoY Diluted EPS
$-66.00
Gross margin
15.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Bionano Genomics, Inc. (BNGO) Q4 2021 Earnings Call
Revenue
$6.30M*
▲ 58% YoY Gross margin
3.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Bionano Genomics, Inc. (BNGO) Q3 2021 Earnings Call
Revenue
$4.66M
▲ 112% YoY Diluted EPS
$-42.00
Gross margin
24.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Bionano Genomics, Inc. (BNGO) Q2 2021 Earnings Call
Revenue
$3.86M
▲ 226.2% YoY Diluted EPS
$-42.00
Gross margin
37.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Bionano Genomics, Inc. (BNGO) Q1 2021 Earnings Call
Revenue
$3.17M
▲ 178.9% YoY Diluted EPS
$-24.00
Gross margin
32.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-07
Bionano Genomics, Inc. (BNGO) Q4 2020 Earnings Call Transcript
Revenue
$3.99M*
▲ 43% YoY Gross margin
29.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Bionano Genomics, Inc. (BNGO) Q3 2020 Earnings Call Transcript
Revenue
$2.20M
▼ 33.7% YoY Diluted EPS
$-48.00
Gross margin
33.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-24
Bionano Genomics, Inc. (BNGO) Q2 2020 Earnings Call Transcript
Revenue
$1.18M
▼ 45.7% YoY Diluted EPS
$-54.00
Gross margin
49.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-14
Bionano Genomics, Inc. (BNGO) Q1 2020 Earnings Call Transcript
Revenue
$1.14M
▼ 38.7% YoY Gross margin
24.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Bionano Genomics, Inc. (BNGO) Q4 2019 Earnings Call
Revenue
$2.79M
▼ 30.5% YoY Gross margin
39.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 webcasts
Key facts
CIK
1411690
CUSIP
09075F404
13F (30d)
44 filings
26 filers
Visit website
Investor relations